Anesthesia · Neuromuscular BlockadeRegulatory Approvalregulatorymid-term

Mylan's Sugammadex Sodium ANDA213915 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 6:30:43 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Mylan's receipt of Abbreviated Approval for Sugammadex Sodium is significant as it allows them to enter the neuromuscular blockade market, potentially disrupting existing market dynamics. Pharma strategy teams should closely monitor competitive responses and pricing strategies as Mylan's entry could reshape the landscape. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 12 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Mylan's entry on market dynamics and pricing strategies. The strongest clinical anchor is Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 8 regulatory and 1 competitive items passed relevance filtering for Mylan.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Sugammadex Sodium under ANDA214368 (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex sodium). This approval positions Mylan to compete in the neuromuscular blockade market, potentially impacting existing players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (mylan); Regulatory pathway relevance (nda). The Abbreviated Approval status indicates a streamlined pathway for Mylan, which could influence regulatory strategies for other companies in similar therapeutic areas.

Key Risks

Elevated medium regulatory exposure for Mylan could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Mylan's entry may lead to increased competition, affecting pricing and market share for existing players in the neuromuscular blockade segment.
Portfolio teams should assess the impact of Mylan's entry on market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor for the launch timeline and any subsequent market reactions from competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from FDA Grants Approval for Sugammadex Sodium under ANDA214368 would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (mylan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex sodium); Regulatory pathway relevance (nda)
FDA document
View source

Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Vibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Approval for Sugammadex Sodium under ANDA214368
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex sodium)
FDA Approves Sugammadex Sodium for Gland Pharma
Humanexa Signalslow relevance
Entity match (sugammadex sodium)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Sub-indication match (nmus rehab)
FDA document
View source
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mylan
Sugammadex Sodium
existing competitors

Commercial impact

medium

Mylan's entry may lead to increased competition, affecting pricing and market share for existing players in the neuromuscular blockade segment.

Regulatory impact

medium

The Abbreviated Approval status indicates a streamlined pathway for Mylan, which could influence regulatory strategies for other companies in similar therapeutic areas.

What to watch

Monitor for the launch timeline and any subsequent market reactions from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.